AC Immune Future Growth
Future criteria checks 2/6
AC Immune is forecast to grow earnings and revenue by 55.3% and 41% per annum respectively while EPS is expected to grow by 55.9% per annum.
Key information
55.3%
Earnings growth rate
55.9%
EPS growth rate
Biotechs earnings growth | 28.2% |
Revenue growth rate | 41.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 17 Sep 2024 |
Recent future growth updates
Recent updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 66 | -30 | 48 | -79 | 3 |
12/31/2025 | 67 | -23 | 23 | 28 | 4 |
12/31/2024 | 11 | -73 | -82 | 29 | 4 |
6/30/2024 | 15 | -61 | 44 | 45 | N/A |
3/31/2024 | 15 | -55 | -43 | -43 | N/A |
12/31/2023 | 15 | -54 | -61 | -60 | N/A |
9/30/2023 | 0 | -68 | -62 | -62 | N/A |
6/30/2023 | 4 | -67 | -62 | -62 | N/A |
3/31/2023 | 4 | -69 | -68 | -67 | N/A |
12/31/2022 | 4 | -71 | -75 | -74 | N/A |
9/30/2022 | 4 | -73 | -76 | -74 | N/A |
6/30/2022 | N/A | -76 | -77 | -75 | N/A |
3/31/2022 | N/A | -75 | -74 | -71 | N/A |
12/31/2021 | N/A | -73 | -68 | -66 | N/A |
9/30/2021 | 1 | -71 | -70 | -67 | N/A |
6/30/2021 | 2 | -74 | -71 | -68 | N/A |
3/31/2021 | 3 | -71 | -69 | -67 | N/A |
12/31/2020 | 15 | -62 | -61 | -60 | N/A |
9/30/2020 | 15 | -62 | -54 | -53 | N/A |
6/30/2020 | 47 | -25 | -22 | -20 | N/A |
3/31/2020 | 48 | -26 | -22 | -20 | N/A |
12/31/2019 | 110 | 45 | 53 | 55 | N/A |
9/30/2019 | 111 | 50 | 55 | 56 | N/A |
6/30/2019 | 80 | 18 | 26 | 27 | N/A |
3/31/2019 | 81 | 24 | 34 | 35 | N/A |
12/31/2018 | 7 | -51 | -46 | -44 | N/A |
9/30/2018 | 22 | -32 | -28 | -26 | N/A |
6/30/2018 | 21 | -27 | -23 | -22 | N/A |
3/31/2018 | 20 | -29 | N/A | -24 | N/A |
12/31/2017 | 20 | -26 | N/A | -22 | N/A |
9/30/2017 | 5 | -35 | N/A | -35 | N/A |
6/30/2017 | 6 | -36 | N/A | -19 | N/A |
3/31/2017 | 25 | -10 | N/A | -10 | N/A |
12/31/2016 | 23 | -7 | N/A | -6 | N/A |
9/30/2016 | 22 | -8 | N/A | -4 | N/A |
6/30/2016 | 45 | 21 | N/A | 21 | N/A |
3/31/2016 | 39 | 17 | N/A | 16 | N/A |
12/31/2015 | 39 | 20 | N/A | 44 | N/A |
9/30/2015 | 65 | 46 | N/A | 45 | N/A |
6/30/2015 | 41 | 21 | N/A | 8 | N/A |
3/31/2015 | 28 | 10 | N/A | 7 | N/A |
12/31/2014 | 30 | 11 | N/A | -18 | N/A |
12/31/2013 | 9 | -11 | N/A | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACIU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACIU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACIU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACIU's revenue (41% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: ACIU's revenue (41% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ACIU's Return on Equity is forecast to be high in 3 years time